NASDAQ : AVXL
Anavex Life Sciences Corp. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 110.31M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year October - September; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 5.93M | 13.82M | 11.04M | 12.05M | 13.14M | 9.15M |
| Research & Development | 11.33M | 36.94M | 39.55M | 41.00M | 34.52M | 28.31M |
| Operating Expenses | 17.27M | 50.76M | 50.59M | 53.05M | 47.66M | 37.45M |
| Operating Income | -17.27M | -50.76M | -50.59M | -53.05M | -47.66M | -37.45M |
| Interest & Investment Income | 4.21M | 4.68M | 7.32M | 6.52M | 947.00K | 26.00K |
| Currency Exchange Gain (Loss) | 51.00K | -332.00K | 189.00K | -40.00K | -904.00K | -266.00K |
| Other Non Operating Income (Expenses) | 37.00K | 75.00K | -939.00K | 54.00K | ||
| EBT Excluding Unusual Items | -13.00M | -46.38M | -43.00M | -47.51M | -47.62M | -37.64M |
| Pretax Income | -13.00M | -46.38M | -43.00M | -47.51M | -47.62M | -37.64M |
| Income Tax Expense | 18.00K | 358.00K | 268.00K | |||
| Net Income | -13.02M | -46.38M | -43.00M | -47.51M | -47.98M | -37.91M |
| Net Income to Common | -13.02M | -46.38M | -43.00M | -47.51M | -47.98M | -37.91M |
| Shares Outstanding (Basic) | 90.07M | 85.29M | 83.47M | 79.79M | 76.91M | 69.80M |
| Shares Outstanding (Diluted) | 90.07M | 85.29M | 83.47M | 79.79M | 76.91M | 69.80M |
| EPS (Basic) | -0.14 | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 |
| EPS (Diluted) | -0.14 | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 |
| EBIT | -17.27M | -50.76M | -50.59M | -53.05M | -47.66M | -37.45M |
Balance sheet
Fiscal year October - September; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 118.33M | 102.58M | 132.19M | 151.02M | 149.16M | 152.11M |
| Cash & Short-Term Investments | 118.33M | 102.58M | 132.19M | 151.02M | 149.16M | 152.11M |
| Other Receivables | 995.00K | 809.00K | 2.45M | 2.71M | 3.19M | 9.14M |
| Receivables | 995.00K | 809.00K | 2.45M | 2.71M | 3.19M | 9.14M |
| Prepaid Expenses | 818.00K | 429.00K | 931.00K | 653.00K | 354.00K | 371.91K |
| Total Current Assets | 120.14M | 103.81M | 135.57M | 154.39M | 152.71M | 161.62M |
| Total Assets | 120.14M | 103.81M | 135.57M | 154.39M | 152.71M | 161.62M |
| Accounts Payable | 3.66M | 4.25M | 9.63M | 4.32M | 3.83M | 4.74M |
| Accrued Expenses | 4.04M | 3.37M | 4.28M | 5.99M | 5.95M | 5.61M |
| Current Unearned Revenue | 1.33M | 1.40M | 2.22M | 444.00K | 443.83K | |
| Total Current Liabilities | 7.69M | 8.95M | 15.30M | 12.53M | 10.21M | 10.80M |
| Total Liabilities | 7.69M | 8.95M | 15.30M | 12.53M | 10.21M | 10.80M |
| Common Stock | 93.00K | 87.00K | 85.00K | 82.00K | 78.00K | 75.92K |
| Additional Paid-In Capital | 498.00M | 477.23M | 456.25M | 434.84M | 387.98M | 348.33M |
| Retained Earnings | -385.64M | -382.45M | -336.07M | -293.07M | -245.56M | -197.59M |
| Shareholders' Equity | 112.45M | 94.87M | 120.26M | 141.85M | 142.49M | 150.82M |
| Total Liabilities & Equity | 120.14M | 103.81M | 135.57M | 154.39M | 152.71M | 161.62M |
| Net Cash (Debt) | 118.33M | 102.58M | 132.19M | 151.02M | 149.16M | 152.11M |
| Net Cash Per Share | 1.31 | 1.20 | 1.58 | 1.89 | 1.94 | 2.18 |
| Filing Date Shares Outstanding | 92.70M | 89.35M | 84.82M | 82.09M | 77.96M | 76.02M |
| Total Common Shares Outstanding | 92.70M | 86.67M | 84.80M | 82.07M | 77.94M | 75.92M |
| Working Capital | 112.45M | 94.87M | 120.26M | 141.85M | 142.49M | 150.82M |
| Book Value Per Share | 1.21 | 1.09 | 1.42 | 1.73 | 1.83 | 1.99 |
| Tangible Book Value | 112.45M | 94.87M | 120.26M | 141.85M | 142.49M | 150.82M |
| Tangible Book Value Per Share | 1.21 | 1.09 | 1.42 | 1.73 | 1.83 | 1.99 |
Cash flow statement
Fiscal year October - September; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -13.02M | -46.38M | -43.00M | -47.51M | -47.98M | -37.91M |
| Stock-Based Compensation | -11.94M | 11.55M | 9.44M | 16.37M | 18.38M | 8.23M |
| Other Operating Activities | 845.00K | |||||
| Change in Accounts Payable | -3.08M | -5.38M | 5.30M | 497.00K | -914.00K | 751.00K |
| Change in Unearned Revenue | -37.00K | -75.00K | 473.00K | 444.00K | ||
| Change in Other Net Operating Assets | -1.24M | 1.20M | -2.48M | 1.53M | 6.28M | -1.90M |
| Operating Cash Flow | -29.29M | -39.04M | -30.81M | -27.79M | -24.24M | -30.38M |
| Issuance of Common Stock | 46.90M | 12.14M | 11.97M | 29.65M | 22.00M | 158.79M |
| Repurchase of Common Stock | -445.00K | -2.71M | ||||
| Other Financing Activities | -707.00K | -5.55M | ||||
| Financing Cash Flow | 46.45M | 9.43M | 11.97M | 29.65M | 21.29M | 153.24M |
| Net Cash Flow | 17.16M | -29.61M | -18.84M | 1.87M | -2.95M | 122.86M |
| Levered Free Cash Flow | -27.06M | -24.39M | -19.43M | -14.28M | -6.03M | -15.90M |
| Unlevered Free Cash Flow | -27.06M | -24.39M | -19.43M | -14.28M | -6.03M | -15.90M |
| Cash Income Tax Paid | 130.00K | 125.00K | 300.00K | 136.00K | 327.00K | 140.00K |
| Change in Working Capital | -4.33M | -4.22M | 2.75M | 2.50M | 5.36M | -706.00K |
Ratios
Fiscal year October - September; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 110.31M | 764.46M | 481.64M | 536.78M | 804.37M | 1.36B |
| Enterprise Value | -8.02M | 663.29M | 342.88M | 381.96M | 651.17M | 1.20B |
| Last Close Price | 1.19 | 8.90 | 5.68 | 6.55 | 10.32 | 17.95 |
| Forward PE | 10.73 | |||||
| PB Ratio | 0.98 | 8.06 | 4.00 | 3.78 | 5.64 | 9.01 |
| P/TBV Ratio | 0.98 | 8.06 | 4.00 | 3.78 | 5.64 | 9.01 |
| Net Debt / Equity Ratio | -1.05 | -1.08 | -1.10 | -1.06 | -1.05 | -1.01 |
| Quick Ratio | 15.51 | 11.56 | 8.80 | 12.27 | 14.92 | 14.93 |
| Current Ratio | 15.62 | 11.61 | 8.86 | 12.32 | 14.95 | 14.97 |
| Return on Equity (ROE) | -12.80% | -43.11% | -32.81% | -33.41% | -32.71% | -42.58% |
| Return on Assets (ROA) | -9.70% | -26.51% | -21.81% | -21.59% | -18.95% | -23.87% |
| Return on Capital Employed (ROCE) | -15.40% | -53.50% | -42.10% | -37.40% | -33.40% | -24.80% |
| Earnings Yield | -12.15% | -6.07% | -8.93% | -8.85% | -5.96% | -2.79% |
| Buyback Yield / Dilution | -5.94% | -2.18% | -4.61% | -3.74% | -10.18% | -19.95% |